Published in J Biol Chem on October 18, 2010
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev (2011) 2.20
Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol (2012) 1.67
Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration. Cell Death Differ (2014) 0.91
The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment. J Biol Chem (2015) 0.85
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene (2015) 0.83
Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc Res (2015) 0.79
ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells. Oncogene (2016) 0.78
Prediction of novel genes associated with negative regulators of toll-like receptors-induced inflammation based on endotoxin tolerance. Inflammation (2012) 0.77
Intrinsic cellular signaling mechanisms determine the sensitivity of cancer cells to virus-induced apoptosis. Sci Rep (2016) 0.76
The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Oncogenesis (2016) 0.76
Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor. Br J Cancer (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2006) 6.64
Anoikis mechanisms. Curr Opin Cell Biol (2001) 6.36
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol (2001) 6.21
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A (1998) 5.34
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell (2006) 4.36
Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol (2003) 4.25
Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res (2009) 3.70
Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene (2008) 3.63
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
Molecular target class is predictive of in vitro response profile. Cancer Res (2010) 3.27
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol (1999) 3.05
Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol (2008) 2.96
BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell (2007) 2.60
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol (2005) 2.20
Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol (2001) 2.02
Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev (2009) 1.93
EGFR family: structure physiology signalling and therapeutic targets. Growth Factors (2008) 1.87
Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J (2002) 1.86
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene (2004) 1.77
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol (2008) 1.65
Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol (2009) 1.52
Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol (2009) 1.52
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res (2006) 1.52
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res (2004) 1.51
Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol (2003) 1.50
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis (2005) 1.48
Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem (2001) 1.46
Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation. J Biol Chem (2001) 1.44
Evidence for direct interaction between Sprouty and Cbl. J Biol Chem (2000) 1.37
G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol (2005) 1.35
Integrins and signal transduction. Adv Exp Med Biol (2010) 1.34
Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res (2006) 1.32
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res (2010) 1.32
Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J Biol Chem (2003) 1.31
Sprouty: how does the branch manager work? J Cell Sci (2003) 1.25
Integrin alpha 2 beta 1-dependent EGF receptor activation at cell-cell contact sites. J Cell Sci (2000) 1.23
ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci (2010) 1.22
Sprouty and cancer: the first terms report. Cancer Lett (2006) 1.22
The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res (2009) 1.20
Live free or die: tales of homeless (cells) in cancer. Am J Pathol (2010) 1.15
ERK pathway positively regulates the expression of Sprouty genes. Biochem Biophys Res Commun (2001) 1.14
A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. J Biol Chem (2006) 1.13
Spatial regulation of EGFR signaling by Sprouty2. Curr Biol (2007) 1.09
ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res (2006) 1.06
Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res (2009) 1.05
Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. J Biol Chem (2007) 1.05
Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. J Biol Chem (2007) 1.03
Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol (2006) 1.03
SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene (2010) 0.99
Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep (2005) 0.97
Muc4/MUC4 functions and regulation in cancer. Future Oncol (2009) 0.95
The regulation of expression of integrin receptors. Proc Soc Exp Biol Med (1997) 0.95
Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. J Biol Chem (2005) 0.89
Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Cancer Cell (2006) 0.88
Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. J Biol Chem (2008) 0.87
Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci (2010) 0.83
Regulator of epidermal growth factor signaling: Sprouty. Methods Mol Biol (2006) 0.82
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol (2003) 4.25
Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol (2002) 4.22
Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A (2003) 4.03
A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell (2007) 3.97
Engineering tumors with 3D scaffolds. Nat Methods (2007) 3.96
Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol (2008) 3.72
p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol (2006) 3.37
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol (2009) 3.26
A non-genetic route to aneuploidy in human cancers. Nat Cell Biol (2011) 3.25
Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol (2002) 2.92
Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A (2004) 2.81
Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron (2005) 2.72
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell (2007) 2.60
Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis. Immunity (2006) 2.57
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci U S A (2004) 2.56
Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature (2012) 2.40
Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol (2003) 2.38
Substrate stiffness regulates cadherin-dependent collective migration through myosin-II contractility. J Cell Biol (2012) 2.33
IL-6 involvement in epithelial cancers. J Clin Invest (2007) 2.29
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev (2011) 2.20
Common effector processing mediates cell-specific responses to stimuli. Nature (2007) 2.20
Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol (2005) 2.20
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Identifying single-cell molecular programs by stochastic profiling. Nat Methods (2010) 2.11
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell (2012) 2.11
Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A (2010) 2.10
The cell biology of cell-in-cell structures. Nat Rev Mol Cell Biol (2008) 1.96
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov (2011) 1.88
Vav GEFs are required for beta2 integrin-dependent functions of neutrophils. J Cell Biol (2004) 1.87
Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A (2007) 1.83
Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia (2004) 1.71
Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res (2006) 1.66
Lumen formation during mammary epithelial morphogenesis: insights from in vitro and in vivo models. Cell Cycle (2007) 1.62
Novel role for PDEF in epithelial cell migration and invasion. Cancer Res (2005) 1.57
A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012) 1.57
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J Cell Biol (2004) 1.56
Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol (2004) 1.40
G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol (2005) 1.35
Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell (2012) 1.26
Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci U S A (2011) 1.26
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One (2010) 1.15
Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res (2009) 1.15
Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal (2012) 1.14
Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2013) 1.11
A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene (2004) 1.11
Regulation of cell adhesion and collective cell migration by hindsight and its human homolog RREB1. Curr Biol (2008) 1.10
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest (2014) 1.05
Activation of NF-kappaB following detachment delays apoptosis in intestinal epithelial cells. Oncogene (2005) 1.04
ErbB2 and TGF-beta: a cooperative role in mammary tumor progression? Cell Cycle (2004) 1.03
PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell (2013) 1.01
A stiff blow from the stroma: collagen crosslinking drives tumor progression. Cancer Cell (2009) 1.01
The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol (2012) 1.01
Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol (2004) 0.98
Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res (2013) 0.95
Tumor self-seeding: bidirectional flow of tumor cells. Cell (2009) 0.94
Tensins: a new switch in cell migration. Dev Cell (2007) 0.91
Psidin, a conserved protein that regulates protrusion dynamics and cell migration. Genes Dev (2011) 0.89
Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis. Mol Biol Cell (2010) 0.88
p63, cell adhesion and survival. Cell Cycle (2007) 0.88
Uncovering a tumor suppressor for triple-negative breast cancers. Cell (2011) 0.86
Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res (2008) 0.85
Transcriptional regulation of metastatic [Id]entity by KLF17. Genome Biol (2009) 0.85
In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. J Vis Exp (2012) 0.84
Evidence for a multipotent mammary progenitor with pregnancy-specific activity. Breast Cancer Res (2013) 0.83
YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell (2009) 0.82
An active form of Vav1 induces migration of mammary epithelial cells by stimulating secretion of an epidermal growth factor receptor ligand. Cell Commun Signal (2006) 0.81
The myosin-II-responsive focal adhesion proteome: a tour de force? Nat Cell Biol (2011) 0.80
Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells. PLoS One (2010) 0.80
Keeping a breast of recent developments in cancer metabolism. Curr Drug Targets (2010) 0.78
SePARating polarity and proliferation in ErbB2 oncogenesis. Nat Cell Biol (2006) 0.77
Mechanistic biology in the next quarter century. Mol Biol Cell (2010) 0.76
[Entosis, a cell death process related to cell cannibalism between tumor cells]. Med Sci (Paris) (2008) 0.76
Direct phosphorylation of focal adhesion kinase by c-Src: evidence using a modified nucleotide pocket kinase and ATP analog. Biochem Biophys Res Commun (2002) 0.76
Corrigendum: Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2016) 0.75
Understanding tumor cell metabolism: the secret to winning the war (burg) on cancer? Semin Cell Dev Biol (2012) 0.75
Rapid Sequential in Situ Multiplexing with DNA Exchange Imaging in Neuronal Cells and Tissues. Nano Lett (2017) 0.75
Correction: Mapping the dynamics of force transduction at cell-cell junctions of epithelial clusters. Elife (2015) 0.75